Vogenx, Inc. 424B4final IPO prospectus

Executive Summary

Vogenx is a pre-revenue biotechnology company developing mizagliflozin, an oral drug intended to moderate intestinal glucose absorption, principally for post-bariatric hypoglycemia. FY2025 net loss narrowed to $(1.45)M as trial spending subsided, but Q1 2026 loss widened 33.3% Y/Y to $(0.475)M as development restarted. Its all-primary IPO raises $81.3M gross at $13.00 per share, implying a $181M market capitalization and giving IPO buyers 44.9% of outstanding shares before option dilution. Investors are funding clinical proof rather than commercial growth: proceeds support two Phase 2 programs and operations through 2028, but not Phase 3 or approval, making subsequent trial results and financing decisive.

The Offering

• Size and implied valuation: 6.25M primary shares at $13.00; $81.3M gross proceeds; $181M market capitalization on 13,917,587 post-offering shares; buyers own 44.9%. Including 561,657 outstanding options gives a fully diluted count of 14,479,244, a $188M capitalization and a 43.2% buyer stake, before future grants. Revenue and earnings multiples are inapplicable because the company has neither revenue nor profits.
• Terms: JonesTrading Institutional Services is sole book-running manager; listing is on the Nasdaq Capital Market as VOGX. Its 45-day option covers 937,500 additional primary shares, bringing gross proceeds to $93.4M and outstanding shares to 14,855,087 if fully exercised. Estimated net proceeds are ≈$73.6M, or ≈$84.9M with full exercise.
• Recipients and spending: proceeds go to Vogenx, not selling shareholders. Planned allocations are ≈$26.3M for the Phase 2b EMERGE hypoglycemia study, ≈$20.4M for gastroparesis proof of concept and ≈$0.844M for accrued expenses, including ≈$0.769M of employee salary and bonus obligations; the remainder supports research, development and corporate needs.
• Dilution: each $13.00 share is backed by $5.24 of net tangible assets after the IPO, a $7.76 gap. Existing holders’ stated average consideration is $1.41 per share. A further 1.75M shares are reserved under the new equity plan but are not outstanding awards.
• Capitalization bridge: preferred shares convert into 1,887,144 common shares, notes into 64,102 shares and cashless warrant exercises produce 453,183 shares. These events leave cash unchanged, eliminate the $0.836M note carrying amount and warrant liability, and move equity from $(1.40)M to $(0.645)M before offering proceeds. The IPO then adds $73.6M to cash and equity.
• Timing and resale: prospectus/pricing date 8/11/2026; delivery expected on or about 8/13/2026. Directors, officers and substantially all shareholders have 180-day lock-ups ending 2/7/2027, subject to early waiver. The 7,667,587 pre-offering shares may subsequently become saleable subject to applicable restrictions.

Key Financial Highlights

$M; historical figures except the explicitly labeled After IPO column. After IPO assumes the conversions, warrant exercises and base offering, net of costs, without the underwriters’ option.

• Spending trajectory: FY2025’s improvement followed completion of the earlier hypoglycemia trial in 2024, not rising sales or proven operating leverage; EMERGE startup drove renewed quarterly R&D spending.
• Cash-flow quality: FY2025 operating cash use benefited from $0.304M of working-capital movements, including deferred compensation. Q1 2026 cash use was cushioned by rising payables and accruals despite offering-cost spending.
• Negative equity: accumulated losses of $(11.3)M exceeded contributed capital; total liabilities of $2.30M were substantially greater than debt of $0.836M, so the deficit was not simply borrowing.
• Runway: management expects funding through 2028, but historical burn understates the cost of larger trials and public-company operations.

Business Model and Growth Drivers

Vogenx’s future revenue depends on approval and sales of licensed drugs, directly or through partners. Mizagliflozin rights exclude Japan, Korea and Taiwan; Kissei is entitled to up to $27.0M in development/regulatory milestones and high-single-digit sales royalties.

• Lead evidence: mizagliflozin has been administered to 532 subjects across 10 studies, but the two hypoglycemia Phase 2 studies included only 24 patients. In a short repeat-dose study, combined Level 2/3 events declined ≈60% across doses; small samples, subgroup effects and short treatment limit conclusions.
• Development catalyst: EMERGE compares two doses taken three times daily against placebo, measuring patient-reported severe events and self-monitored low-glucose events. Recruitment is expected in 2026 and topline results in 2027.
• Market opportunity: no approved pharmacologic hypoglycemia treatment exists; cited U.S. estimates range from more than 160,000 symptomatic patients requiring management to more than 450,000 experiencing Level 2/3 events. These are uncertain populations, not established paying customers.
• Expansion strategy: a gastroparesis Phase 2 study is planned for 2027. Cushing’s syndrome and preclinical weight-maintenance programs add optionality but require further funding. Four full-time employees and one part-time employee, as of 5/15/2026, rely heavily on external development and manufacturing partners.

Governance and Control

• Voting influence: common shares carry one vote each; directors and executives beneficially own 33.2% after the IPO. CEO James Green and Chief Scientific Officer William Wilkison each hold 13.7%, giving insiders substantial influence without majority ownership.
• Entrenchment: a staggered board, two-thirds removal threshold, restrictions on shareholder action and executive nomination rights make leadership changes or takeovers harder.
• Related-party funding: December 2025 notes supplied $0.750M from director-associated parties, a scientific founder’s family-associated entity and the CFO; conversion generally occurs at a 10% IPO-price discount.
• Compensation and dilution: post-offering executive base salaries total $1.48M annually, with 50% target bonuses. The new equity plan reserves 1.75M shares and permits annual reserve increases of 5% beginning in 2027, increasing future expense and dilution potential.

Risk Assessment

• Audit and controls: the auditor flagged substantial going-concern doubt, annual statements were restated for EPS errors, and staffing, segregation-of-duties and systems-access weaknesses require remediation.
• Clinical concentration: value depends principally on mizagliflozin; 24-patient hypoglycemia evidence may not replicate, while diarrhea and three-times-daily dosing could affect tolerability and adoption.
• Financing and valuation: the $181M implied valuation rests on unapproved assets, and proceeds cannot fund Phase 3 or approval; adverse results or capital-market conditions could force dilution or program cuts.
• Competition and market size: Amylyx’s avexitide entered Phase 3 in 2025, ahead of Vogenx; uncertain diagnosis and declining bariatric surgery could shrink the eligible market.
• License and protection: losing Kissei rights could halt development, while licensed patents expire in 2028, 2029 and 2033; later owned protection may not provide equivalent commercial coverage.
• Key-person dependence: discovery has historically relied on scientific co-founder Wilkison, so his loss could disrupt pipeline development.
• Outsourced execution: minimal staffing and reliance on contractors without broadly secured manufacturing capacity expose trials to enrollment, quality and supply delays.

Investor Actionables

At $13.00, buyers must accept that early efficacy signals can become reproducible clinical benefit and ultimately commercial demand. Proceeds primarily purchase Phase 2 evidence, not a funded route to launch.

• EMERGE validation: against preliminary ≈60% event reduction, check the company’s planned 2027 results for meaningful event reduction and tolerability; weak efficacy or persistent treatment-limiting diarrhea undermines the lead thesis.
• Gastroparesis expansion: track the planned 2027 study and $20.4M allocation; positive gastric-emptying evidence supports diversification, while delays or negative results leave value concentrated in hypoglycemia.
• Funding execution: test the through-2028 runway against actual trial spending, compensation and liabilities; advancing studies within available cash supports the plan, while an early raise signals higher funding needs.
• Reporting repair: management plans control remediation during FY2026; subsequent filings should show resolved weaknesses and reliable reporting rather than recurring restatements.